Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Dose-Finding Study of MK-0822 in the Treatment of Involutional Osteoporosis
NCT00620113 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Dose-Finding Study of MK-0822 in the Treatment of Involutional Osteoporosis
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 3, 2007
- Completion date
- May 29, 2009
- Enrollment
- 287 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
osteoporosis postmenopausal